27655-40-9

Basic information

• Product Name: 5-Isoquinolinesulfonic acid
• Synonyms: ISOQUINOLINE-5-SULFONIC ACID;ISOQUINOLINE-5-SULFONIC ACID FOR SINTESIS;ISOQUINOLINE-5-SULPHONIC ACID;5-SULFOISOQUINOLINE;5-ISOQUINOLINESULFONIC ACID;5-ISOQUINOLINESULFONIC ACID MONOHYDRATE;5-ISOQUINOLINESULPHONIC ACID;Isoquinoline-5-SulphonicAcid99%
• CAS NO: 27655-40-9
• Molecular Formula: C₉H₇NO₃S
• Molecular Weight: 209.22178
• EINECS: 1308068-626-2
• Product Categories: Quinolines, Isoquinolines & Quinoxalines;Organic acids;Aromatics Compounds;Aromatics;Sulfur & Selenium Compounds;Quinolines, Isoquinolines & Quinoxalines;Building Blocks;Heterocyclic Building Blocks;Isoquinolines
• Mol File: 27655-40-9.mol

Chemical Properties

• Melting Point: 300 °C
• Appearance: /Solid
• Density: 1.4048 (rough estimate)
• Refractive Index: 1.5364 (estimate)
• Storage Temp.: -20?C Freezer
• PKA: -0.98±0.40(Predicted)
• CAS DataBase Reference: 5-Isoquinolinesulfonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoquinolinesulfonic acid(27655-40-9)
• EPA Substance Registry System: 5-Isoquinolinesulfonic acid(27655-40-9)

Safety Data

• Hazard Codes: T,C,Xi
• Statements: 49-23-34-24-36/38
• Safety Statements: 53-26-27-36/37/39-45
• RIDADR: UN 2585 8/PG 3
• WGK Germany: 1
• TSCA: Yes
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 27655-40-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Isoquinolinesulfonic acid is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its ability to form conjugates with oligoarginine peptides makes it a valuable component in the synthesis of novel drug candidates.
Used in Chemical Synthesis:
As a white crystalline solid, 5-Isoquinolinesulfonic acid serves as a key building block in the synthesis of a wide range of chemical compounds. Its unique structure allows for various chemical reactions, making it a useful starting material for the creation of new molecules with potential applications in different industries.
Used in Research and Development:
5-Isoquinolinesulfonic acid is also utilized in research and development settings, where it can be employed to study the properties and behavior of related compounds. Its use in the synthesis of conjugates with oligoarginine peptides highlights its potential in exploring new avenues in drug discovery and development.

InChI:InChI=1/C9H7NO3S/c11-14(12,13)9-3-1-2-7-6-10-5-4-8(7)9/h1-6H,(H,11,12,13)/p-1

Upstream product

• 119-65-3 isoquinoline 
• 7664-93-9 sulfuric acid 
• 7732-18-5 water 
• 5984-79-2 isoquinoline; hydrogen sulfate 
• 105627-79-0 isoquinoline-5-sulfonyl chloride hydrochloride 

Downstream Products

• 105627-79-0 isoquinoline-5-sulfonyl chloride hydrochloride 
• 2439-04-5 5-hydroxyisoquinoline 
• 129305-12-0 Toluene-4-sulfonic acid 2-(isoquinoline-5-sulfonylamino)-ethyl ester 
• 116970-54-8 Isoquinoline-5-sulfonic acid benzyl-(2-hydroxy-ethyl)-amide 
• 116970-50-4 N-(2-aminoethyl)-5-isoquinoline-sulphonamide hydrochloride 
• 116970-62-8 N-[2-(methylamino)ethyl]-5-isoquinoline sulfonamide hydrochloride 
• 116970-88-8 Isoquinoline-5-sulfonic acid (2-amino-ethyl)-benzyl-amide; hydrochloride 
• 116970-70-8 Isoquinoline-5-sulfonic acid (2-cyclohexylamino-ethyl)-amide; hydrochloride 
• 116970-75-3 Isoquinoline-5-sulfonic acid [2-(cyclohexyl-methyl-amino)-ethyl]-amide; hydrochloride 
• 116970-71-9 Isoquinoline-5-sulfonic acid (2-benzylamino-ethyl)-amide; hydrochloride 
• 116970-74-2 Isoquinoline-5-sulfonic acid (2-phenethylamino-ethyl)-amide; hydrochloride 
• 116970-72-0 Isoquinoline-5-sulfonic acid [2-(4-methoxy-benzylamino)-ethyl]-amide; hydrochloride 
• 116970-59-3 Isoquinoline-5-sulfonic acid [2-(3-chloro-benzylamino)-ethyl]-amide; hydrochloride 
• 116970-58-2 Isoquinoline-5-sulfonic acid [2-(4-chloro-benzylamino)-ethyl]-amide; hydrochloride 

Relevant articles and documents

Preparation method of tetrahydroisoquinoline derivative

The invention discloses a preparation method of a tetrahydroisoquinoline derivative which is N-Fmoc-1,2,3,4-tetrahydroisoquinoline-5-alcohol. The preparation method comprises the following steps: taking isoquinoline as a starting raw material, loading sulfonic acid groups, hydrolyzing, hydrogenating and carrying out Fmoc protection to obtain a target product. The compound is used as an important medical intermediate.

ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.

Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor

VEGFR, ERK and Abl had been respectively identified as good drug targets, and their crosstalk also had been well elaborated. Multitarget drugs were more advantageous for cancer treatment, however, no inhibitors simultaneously acting on the three proteins were developed due to their structural diversities. Herein, N-(4-((2-(2-(naphthaen-1-yl)acetamido)ethyl)carbamoyl)piperidin-4-yl)-6- (trifluoromethyl)nicotinamide (NEPT, 6a) was discovered as an active scaffold against VEGFR-2, ERK-2 and Abl-1 kinases through the combination of support vector machine, similarity searching and molecular docking. NEPT and its derivatives were synthesized by convenient routine, their in vitro anti-proliferative abilities against human liver cancer cell line HepG2 were preliminarily evaluated. A representative compound 6b showed an IC50 value of 11.3 μM and induced significant HepG2 cells apoptosis. Besides, these compounds displayed better anti-proliferative abilities against K562 cells (a cell line with typical hyperactivity of the above multikinases), for example compound 6b exhibited an IC50 value of 4.5 μM. Based on hepatotoxicity case reports of Abl inhibitors, cytotoxicity of synthetic compounds against normal liver cell lines (QSG7701 and HL7702) was studied, 6b had a similar toxic effect with positive control imatinib, and most compounds showed less than 35% inhibition activities at 100 μM. Molecular docking study disclosed interactions of 6b with VEGFR-2, ERK-2 and Abl-1 kinases, respectively. Our data suggested the biological activities of 6b may derived from collaborative effects of VEGFR-2, ERK-2 and Abl-1 inhibition.

De novo design and synthesis of HIV-1 integrase inhibitors

Existing AIDS therapies are out of reach for most HIV-infected people in developing countries and, where available, they are limited by their toxicity and their cost. New anti-HIV agents are needed urgently to combat emerging viral resistance and reduce the side effects associated with currently available drugs. Toward this end, LeapFrog, a de novo drug design program was used to design novel, potent, and selective inhibitors of HIV-1 integrase. The designed compounds were synthesized and tested for in vitro inhibition of HIV-1 integrase. Out of the 25 compounds that were designed, and synthesized, four molecules (compounds 23, 26, 43, and 59) showed moderate to low inhibition of HIV-1 integrase for 3′-processing and 3′- strand transfer activities. Nonetheless, these compounds possess structural features not seen in known HIV-1 integrase inhibitors and thus can serve as excellent leads for further optimization of anti-HIV-1 integrase activity.

SYNTHESIS OF POTENTIAL &β-BLOCKERS DERIVED FROM 5-HYDROXYISOQUINOLINE

The synthesis of N-substituted amides 5-hydroxyisoquinaldate is described.Keywords: 5-hydroxyisoquinoline derivatives, synthesis, elemental and spectral analysis.